Investigational drug may hold benefit for patients with lung and ovarian cancers

Investigational drug may hold benefit for patients with lung and ovarian cancers

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.